The review found no eligible studies for this question.
Three doses HPV vaccine showed no clear difference in penile or anal intraepithelial neoplasia at up to 3‐year compared with control (low certainty).
Three doses HPV vaccine probably leads to lower external genital lesions (any genotype) at up to 3‐year compared with control (moderate certainty).
Three doses HPV vaccine probably leads to lower anogenital warts at up to 3‐year compared with control (moderate certainty).
Three doses HPV vaccine leads to higher overall local/injection site adverse events at 15‐day compared with control (high certainty).
Three doses HPV vaccine showed no clear difference in overall systemic events and general symptoms at 15‐day compared with control (moderate certainty).
It is very uncertain whether three doses HPV vaccine changes serious adverse events at up to 3‐year compared with control (very low certainty).
Three doses HPV vaccine may leads to lower mortality at up to 3‐year compared with control (low certainty).